Beyond AI pilots: Pharma needs AI-native operating models, n...
Industry must build custom solutions that leverage a pharmaceutical business’ unique assets – including its people.
Newsletters and Deep Dive digital magazine
Industry must build custom solutions that leverage a pharmaceutical business’ unique assets – including its people.
An AI system can be cheap to buy and expensive to stop.
The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.
Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.
AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.
Editor's Picks
Newsletters and Deep Dive
digital magazine